Literature DB >> 19417598

Massive blood transfusions: the impact of Vietnam military data on modern civilian transfusion medicine.

Ronald D Miller1.   

Abstract

To determine the coagulation defects associated with massive blood transfusions, coagulation studies were performed on 21 battle casualties admitted to the US Naval Support Activity Hospital, Da Nang, Vietnam. All but one patient who received less than 20 units of Acid-Citrate-Dextrose blood (7 patients) did not develop a coagulopathy. All patients who received more than 20 units (14 patients) developed a clinically significant coagulation defect. Although the partial thromboplastin and prothrombin times were markedly prolonged (i.e., low Factor V and XIII levels), restoring these times to normal levels by fresh frozen plasma administration did not terminate the clinical coagulopathy.In all 12 patients who had platelet counts less than 60,000/mm(3), a clinical bleeding problem (coagulopathy) developed. The coagulopathy eventually spontaneously resolved (n = 4), was successfully treated with fresh blood (n = 4), or the patients died (n = 4). A mathematical analysis confirmed that the thrombocytopenia is dilutional in origin and is the primary cause of a coagulopathy from massive blood transfusions. The authors conclude that clinically important coagulopathies predictably occur after administration of 20-25 units of stored Acid-Citrate-Dextrose blood in acutely wounded, previously healthy soldiers. Fresh frozen plasma should not be a major therapeutic choice for coagulopathies in massive blood transfusions. Treatment of dilutional thrombocytopenia (50,000/mm(3)) is a primary component of treating coagulopathies associated with massive blood transfusions.

Entities:  

Mesh:

Year:  2009        PMID: 19417598     DOI: 10.1097/ALN.0b013e3181a1fd54

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

1.  Toward a definition of "fresh" whole blood: an in vitro characterization of coagulation properties in refrigerated whole blood for transfusion.

Authors:  David Jobes; Yanika Wolfe; Daniel O'Neill; Jennifer Calder; Lisa Jones; Deborah Sesok-Pizzini; X Long Zheng
Journal:  Transfusion       Date:  2011-01       Impact factor: 3.157

2.  The plasma and platelet are important in reducing the mortality in surgical massive blood transfusion: a large multicenter study in China.

Authors:  Zhan-Kui Jin; Yang Sun; Qian-Li Dang; Li-Jie Zhang; Ling Li; Yong-Gang Xu; Hong-Nan Chen; Cui-Xiang Xu; Yao-Jun Song; Jiang-Cun Yang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  Combat: Initial Experience with a Randomized Clinical Trial of Plasma-Based Resuscitation in the Field for Traumatic Hemorrhagic Shock.

Authors:  Michael P Chapman; Ernest E Moore; Theresa L Chin; Arsen Ghasabyan; James Chandler; John Stringham; Eduardo Gonzalez; Hunter B Moore; Anirban Banerjee; Christopher C Silliman; Angela Sauaia
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

4.  Massive Bleeding and Massive Transfusion.

Authors:  Andreas Meißner; Peter Schlenke
Journal:  Transfus Med Hemother       Date:  2012-03-12       Impact factor: 3.747

5.  Investigation of the current situation of massive blood transfusion in different surgical departments: a large multicenter study in China.

Authors:  Yang Sun; Zhan-Kui Jin; Cui-Xiang Xu; Qian-Li Dang; Li-Jie Zhang; Hong-Nan Chen; Yao-Jun Song; Jiang-Cun Yang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

6.  Coagulation defects associated with massive blood transfusion: A large multicenter study.

Authors:  Jiang-Cun Yang; Yang Sun; Cui-Xiang Xu; Qian-Li Dang; Ling Li; Yong-Gang Xu; Yao-Jun Song; Hong Yan
Journal:  Mol Med Rep       Date:  2015-06-22       Impact factor: 2.952

7.  Investigation of the status quo of massive blood transfusion in China and a synopsis of the proposed guidelines for massive blood transfusion.

Authors:  Jiang-Cun Yang; Qiu-Shi Wang; Qian-Li Dang; Yang Sun; Cui-Xiang Xu; Zhan-Kui Jin; Ting Ma; Jing Liu
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.